Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

Completed · Phase 1

Conditions studied: Acne Vulgaris

In brief

This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.

Key facts

Study ID

NCT02218034

Run by

Allergan

People needed

78

Starts

2014-08-01

Expected to finish

2015-03-01

Last updated by the study team

2015-04-30

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of acne vulgaris on the face
• No tobacco use for the past 30 days, and willing to refrain from nicotine use during the study
• Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet light (eg, sunlight, tanning beds) and extremes in weather, such as wind or cold, throughout the study
• If male, willing to maintain routine shaving regimen for the duration of the study and avoid shaving 12 hours prior to specified visits
• Females of childbearing potential must use a reliable method of contraception

You may not qualify if…

• Use of phototherapy devices (eg, ClearLight™) and adhesive cleansing strips (eg, Ponds® and Biore®), as well as cosmetic procedures (eg, facials, peeling, and comedone extraction) in the area to be treated in the past 1 week
• Use of topical anti-inflammatory drugs, salicylic acid (eg, Clearasil® and Clean \& Clear®), corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]), retinoids, and other topical acne treatments (eg, photodynamic therapy, laser therapy, and medicated soaps) in the area to be treated in the past 2 weeks
• Ability to abstain from caffeine-containing products on the dates instructed

Where it is running

• Study site — College Station, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.